BETTA PHARMACEUTICALS: The first prescription for Enasidenib Hydrochloride Capsules has been issued in the United States
BETTA PHARMACEUTICALS announced that the innovative drug ensartinib hydrochloride capsules, jointly developed by the company and its holding subsidiary, has issued its first prescription at the Martin O'Neill Cancer Center in California, USA. Ensartinib is a new generation of highly potent and selective anaplastic lymphoma kinase inhibitor, which is expected to be approved by the U.S. FDA for market launch in December 2024, becoming the first small molecule targeted innovative drug for lung cancer globally launched by a Chinese company
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments